Health

New Parkinson's drug approved in the US: What does it do differently?

The U.S. Food and Drug Administration approved a new Parkinson's pill from the dopamine agonist class, taken once daily and acting selectively on receptors that researchers have tried to target for decades. In trials, AbbVie’s new drug improved patients' movement and daily functioning.